Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2025.25142
Abstract: BACKGROUND The phase 3 PERSEUS trial demonstrated superior efficacy of daratumumab (D), bortezomib (V), lenalidomide (R), and dexamethasone (d) induction/consolidation followed by DR maintenance (DVRd/DR) vs VRd induction/consolidation followed by R maintenance (VRd/R) in transplant-eligible… read more here.
Keywords: negative status; maintenance; mrd negative; cost per ... See more keywords
Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.776920
Abstract: Objective To explore the prognostic significance of the stage at which a minimal residual disease (MRD)-negative status is achieved for patients with newly diagnosed multiple myeloma (NDMM) who received autologous hematopoietic stem cell transplantation (ASCT).… read more here.
Keywords: mrd negative; stage; three groups; groups reached ... See more keywords